Previous 10 | Next 10 |
Acer Therapeutics (NASDAQ:ACER) said the U.S. Food and Drug Administration (FDA) has not yet made a decision on its application for ACER-001 seeking approval of the drug for urea cycle disorders (UCDs). The FDA had accepted the company's new drug application (NDA) for review on...
NEWTON, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced th...
Gainers: Yumanity Therapeutics YMTX +46%. Babylon (BBLN) +11%. Sema4 (SMFR) +11%. Nano-X Imaging (NNOX) +10%. Satsuma Pharmaceuticals (STSA) +10%. Losers: Praxis Precision Medicines PRAX -63%. eFFECTOR Therapeutics (EFTR) -20%. Pear Therapeutics (PEAR) ...
Acer Therapeutics (ACER) -17%. Energy Focus (EFOI) -9% after secures $3.5M capital in private placement. Gevo (GEVO) -8% on pricing $150M securities offering. Context Therapeutics (CNTX) -7%. Bright Green (BGXX) -6%. Red Robin Gourmet Burgers (RRGB) -5% on report...
Gainers: Scholar Rock (SRRK) +26%. Phathom Pharmaceuticals (PHAT) +12%. 4d Pharma (LBPS) +10%. Ocular Therapeutix (OCUL) +9%. Magenta Therapeutics (MGTA) +8%. Losers: PolarityTE (PTE) -34%. Tonix Pharmaceuticals (TNXP) -22%. Albireo Pharma (ALBO) ...
Acer Therapeutics press release (NASDAQ:ACER): Q1 GAAP EPS of -$0.65 misses by $0.37. “Progress in Q1 2022 was marked by a transformative debt financing in March, with continued advancement toward potential commercial launch of ACER-001 for UCDs and further development of our other pip...
NEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported fin...
This week is another big week for the stock market, with CPI data coming on Wednesday. To identify peak inflation and a hopeful tipping point for the economy, traders await feverishly for some resolve. In the meantime, it doesn’t matter if you’re trading penny stocks o...
Acer Therapeutics (NASDAQ:ACER) reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for its phase 3 study of its experimental therapy Edsivo (celiprolol) for the treatment of patients with COL3A1-positive vascular Ehlers-Danlos Syndr...
NEWTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it ...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023